Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association

Безопасность статинов и связанные с ними нежелательные явления: научное заявление Американской кардиологической ассоциации
Robert Lee Page II, Michael J. Miller, Eliot A. Brinton, Lynne T. Braun, Terry A. Jacobson, Paul Barton Duell, Jonathan A. Tobert, Connie B. Newman, David Preiss, Larry B. Goldstein, Clifford C. Chin, Lisa R. Tannock, Geetha Raghuveer, Amy West Pollak, Francine K. Welty
2019-01-17

adverse eventshepatotoxicityrhabdomyolysisstatin safetystatin-induced diabetes mellitus
One in 4 Americans >40 years of age takes a statin to reduce the risk of myocardial infarction, ischemic stroke, and other complications of atherosclerotic disease. The most effective statins produce a mean reduction in low-density lipoprotein cholesterol of 55% to 60% at the maximum dosage, and 6 of the 7 marketed statins are available in generic form, which makes them affordable for most patients. Primarily using data from randomized controlled trials, supplemented with observational data where necessary, this scientific statement provides a comprehensive review of statin safety and tolerability. The review covers the general patient population, as well as demographic subgroups, including the elderly, children, pregnant women, East Asians, and patients with specific conditions such as chronic disease of the kidney and liver, human immunodeficiency viral infection, and organ transplants. The risk of statin-induced serious muscle injury, including rhabdomyolysis, is <0.1%, and the risk of serious hepatotoxicity is ≈0.001%. The risk of statin-induced newly diagnosed diabetes mellitus is ≈0.2% per year of treatment, depending on the underlying risk of diabetes mellitus in the population studied. In patients with cerebrovascular disease, statins possibly increase the risk of hemorrhagic stroke; however, they clearly produce a greater reduction in the risk of atherothrombotic stroke and thus total stroke, as well as other cardiovascular events. There is no convincing evidence for a causal relationship between statins and cancer, cataracts, cognitive dysfunction, peripheral neuropathy, erectile dysfunction, or tendonitis. In US clinical practices, roughly 10% of patients stop taking a statin because of subjective complaints, most commonly muscle symptoms without raised creatine kinase. In contrast, in randomized clinical trials, the difference in the incidence of muscle symptoms without significantly raised creatinine kinase in statin-treated compared with placebo-treated participants is <1%, and it is even smaller (0.1%) for patients who discontinued treatment because of such muscle symptoms. This suggests that muscle symptoms are usually not caused by pharmacological effects of the statin. Restarting statin therapy in these patients can be challenging, but it is important, especially in patients at high risk of cardiovascular events, for whom prevention of these events is a priority. Overall, in patients for whom statin treatment is recommended by current guidelines, the benefits greatly outweigh the risks.
1
About 10% of patients in US clinical practice discontinue statins because of subjective complaints, commonly muscle symptoms without elevated creatine kinase; randomized trials report a smaller treatment-placebo difference.
2
In patients with cerebrovascular disease, possible increases in hemorrhagic stroke are outweighed by larger reductions in atherothrombotic stroke, total stroke, and other cardiovascular events.
3
Statin-associated newly diagnosed diabetes occurs at an approximate rate of 0.2% per year, depending on baseline diabetes risk.
4
Statins reduce low-density lipoprotein cholesterol by 55% to 60% at maximum dosage, and most marketed statins are available generically.
5
The risk of serious statin-induced muscle injury, including rhabdomyolysis, is below 0.1%, while serious hepatotoxicity occurs in approximately 0.001% of patients.
6
The statement finds no convincing causal evidence linking statins to cancer, cataracts, cognitive dysfunction, peripheral neuropathy, erectile dysfunction, or tendonitis.

Statin therapy in patients at risk of atherosclerotic cardiovascular disease, including diverse demographic and clinical subgroups

Statin safety and tolerability, including the incidence and clinical significance of adverse events across patient populations

Publication Details
Publication Date
2019-01-17
Journal
Publisher
ISSN
Cited by
760
Access Type
Author Information
Authors
Robert Lee Page II
Michael J. Miller
Eliot A. Brinton
Lynne T. Braun
Terry A. Jacobson
Paul Barton Duell
Jonathan A. Tobert
Connie B. Newman
David Preiss
Larry B. Goldstein
Clifford C. Chin
Lisa R. Tannock
Geetha Raghuveer
Amy West Pollak
Francine K. Welty
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%